KEAP1 and cancer: Because KEAP1 and Nrf2 are mutated in many cancer types, particularly in chemotherapy-resistant tumors, targeting pathways that do not rely upon a wild type KEAP1 to suppress Nrf2 is necessary for successful drug development.